NK vs. IMTX, MESO, RLAY, RGNX, CRGX, AUTL, BCRX, HLVX, PRME, and NVAX
Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Immatics (IMTX), Mesoblast (MESO), Relay Therapeutics (RLAY), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), BioCryst Pharmaceuticals (BCRX), HilleVax (HLVX), Prime Medicine (PRME), and Novavax (NVAX). These companies are all part of the "medical" sector.
Immatics (NASDAQ:IMTX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
NantKwest received 248 more outperform votes than Immatics when rated by MarketBeat users. However, 71.43% of users gave Immatics an outperform vote while only 53.63% of users gave NantKwest an outperform vote.
64.4% of Immatics shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 71.7% of NantKwest shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Immatics had 1 more articles in the media than NantKwest. MarketBeat recorded 1 mentions for Immatics and 0 mentions for NantKwest. NantKwest's average media sentiment score of 0.00 equaled Immatics'average media sentiment score.
Immatics has a net margin of -179.67% compared to Immatics' net margin of -76,658.58%. NantKwest's return on equity of -43.58% beat Immatics' return on equity.
NantKwest has lower revenue, but higher earnings than Immatics. NantKwest is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.
Immatics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500.
Summary
Immatics beats NantKwest on 9 of the 15 factors compared between the two stocks.
Get NantKwest News Delivered to You Automatically
Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantKwest Competitors List
Related Companies and Tools
